Sionna Therapeutics (SION) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Company background and mission

• Focused on revolutionizing cystic fibrosis (CF) treatment using first-in-class NBD1 stabilizers, aiming to disrupt a market long dominated by a single player.

• Originated from Genzyme and Sanofi science, with Sionna formed in 2019 to accelerate CF research.

• Currently advancing multiple NBD1 programs and complementary mechanisms in clinical development.

Scientific rationale and innovation

• NBD1 is a critical domain in the CFTR protein, with the F508del mutation affecting 90% of CF patients and causing protein instability.

• Existing therapies like TRIKAFTA do not directly stabilize NBD1, leaving room for improvement.

• NBD1 was long considered undruggable due to shallow binding pockets, but Sionna has developed two clinical-stage NBD1 stabilizers.

• Preclinical data show NBD1 stabilization can restore CFTR protein half-life to normal levels.

Clinical development and study design

• The phase 2a PreciSION-CF study tests SION-719 added to TRIKAFTA in F508del homozygous patients, aiming to show sweat chloride improvement as a biomarker of CFTR function.

• Study uses a crossover design with each patient as their own control, targeting a 10 mmol/L sweat chloride improvement, considered clinically meaningful.

• Patient population is carefully selected for homogeneity and room for improvement on TRIKAFTA.

• Data readouts for both the PreciSION-CF and dual combination studies are expected in mid-2026, with more precise timing to be announced after full enrollment.